Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target refers to any tissue or organ that selectively accumulates a radiopharmaceutical based on ligand-specific uptake and retention, allowing gamma-ray emission to be detected by external imaging tools such as gamma cameras or SPECT scanners. Common diagnostic radiopharmaceuticals exploit biological processes (e.g., glucose metabolism) or organ-specific transport to concentrate in areas of interest (such as tumors, inflamed regions, or functioning myocardium), leading to emission of gamma photons. These photons penetrate body tissues and are captured by imaging devices that reconstruct the anatomical and functional distribution of the tracer, thus facilitating diagnosis, staging, and treatment planning in conditions like cancer, heart disease, and neurologic disorders.
Ligand-specific targeting: Radiopharmaceutical binds a physiological process or molecular structure in tissue or organ, emits gamma rays detected externally
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diagnostic tissue or organ via ligand-specific uptake (gamma-emitting radiopharmaceutical).